The DayOne Accelerator Program, a three-month, equity-free initiative based in Basel, Switzerland, is now accepting applications from early-stage global healthtech and techbio startups. It specifically targets ventures focused on pharmaceutical research and development, offering a structured pathway for innovation within a major European life sciences hub.

The DayOne program is equity-free and fee-free, a non-dilutive growth opportunity crucial for pre-seed to Series A companies managing cash flow and valuation. According to fundsforNGOs, it supports ventures that have raised less than USD 10 million in dilutive funding, clearly defining its target cohort.

What We Know So Far

  • The DayOne Accelerator is a three-month hybrid program located in Basel, Switzerland, according to fundsforNGOs.
  • It specifically invites applications from healthtech and techbio startups working on pharmaceutical R&D, as reported by the same source.
  • The program is structured to be both equity-free and fee-free for all participating startups, the program details state.
  • Applicants must have raised less than USD 10 million in dilutive funding to be considered for a spot in the cohort.
  • Selected high-performing ventures may become eligible for up to CHF 50,000 in non-dilutive funding after the program concludes, fundsforNGOs reports.
  • Initial support includes potential travel assistance of up to CHF 1,000 for an in-person bootcamp in Basel.